Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease

Journal of Neurochemistry

Volumn 82, Issue 3, 2002, Pages 615-624

  Breidert, T ^a   Callebert, J ^b   Heneka, M T ^c   Landreth, G ^d   Launay, J M ^b   Hirsch, E C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c UNIVERSITY OF BONN   (Germany)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glia; Inflammation; MPTP; Parkinson's disease; Peroxisome proliferator activated receptor ; Pioglitazone

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; EXPERIMENTAL MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICROGLIA; MOUSE; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ADMINISTRATION, ORAL; ANIMALS; CELL COUNT; CELL SURVIVAL; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; HOMOVANILLIC ACID; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; MACROPHAGE-1 ANTIGEN; MALE; MICE; MICE, INBRED C57BL; NEUROGLIA; NEURONS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PARKINSONIAN DISORDERS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SUBSTANTIA NIGRA; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TYROSINE 3-MONOOXYGENASE;

ANIMALIA;

EID: 0036326074     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2002.00990.x     Document Type: Article

References (45)

1. Microglial response to 6-hydroxydopamine-induced substantia nigra lesions
2. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity
3. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-delta12,14-prostaglandin J2 in the regulation of microglial functions
4. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease
5. Activated microglia mediate neuronal cell injury via a nitric oxide mechanism
6. Inflammatory mechanisms in Alzheimer's disease: Inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists
7. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system
8. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo
9. Peroxisome proliferatoractivated receptors in inflammation control
10. Suppression of experimental autoimmune encephalomyelitis by pioglitazone, a PPAR-gamma agonist
11. Minocycline reduces microglia activation in the chronic MPTP mouse model of Parkinson's disease
12. Microglia responses in the CNS following sciatic nerve transection in C57BL/WId(s) and BALB/c mice
13. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum
14. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo
15. Glial cells and Parkinson's disease
16. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
17. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease
18. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease
19. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
20. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
21. Regulation of glucose transport by pioglitazone in cultured muscle cells
22. Regional difference in susceptibility to lipopolysaccharideinduced neurotoxicity in the rat brain: Role of microglia
23. Microglia: A sensor for pathological events in the CNS
24. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse
25. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure
26. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain
27. Microglial activation and dopaminergic cell injury: An in vitro model relevant to Parkinson's disease
28. Peroxisome proliferatoractivated receptor gamma-dependent repression of the inducible nitric oxide synthase gene
29. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease
30. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide
31. Naloxone prevents microgliainduced degeneration of dopaminergic substantia nigra neurons in adult rats
32. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys
33. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
34. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients
35. Acute administration of 1-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a compound producing parkinsonism in humans, stimulates [2-14C] deoxyglucose uptake in the regions of the catecholaminergic cell bodies in the rat and guinea pig brains
36. Administration of MPTP acutely increases glucose utilization in the substantia nigra of primates
37. Mechanisms of MPTP toxicity
38. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
39. Pioglitazone: Mechanism of action
40. Sites and mechanisms of function-related changes in energy metabolism in the nervous system
41. Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes
42. Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice
43. Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast
44. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta